Search Results - "Chong, Geoffrey"

Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI by Wight, Joel C., Chong, Geoffrey, Grigg, Andrew P., Hawkes, Eliza A.

“…Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes. Despite the majority of patients being cured with combination…”
Get full text

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study by Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P, Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K, Tam, Constantine S

“…Abstract Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma…”
Get full text

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study by Mooi, Jennifer, Chionh, Fiona, Savas, Peter, Da Gama Duarte, Jessica, Chong, Geoffrey, Brown, Stephen, Wong, Rachel, Price, Timothy J, Wann, Alysson, Skrinos, Effie, Mariadason, John M, Tebbutt, Niall C

“…To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic…”
Get full text

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study by Barraclough, Allison, Agrawal, Shivam, Talaulikar, Dipti, Chong, Geoffrey, Yoo, Edward, Cheah, Chan Y, Franco, Nunzio, Nguyen, Bianca, Mutsando, Howard, Tahir, Fatima, Trotman, Judith, Huang, Jing, Keane, Colm, Lincoln, Mitchel, Cochrane, Tara, Johnston, Anna M, Dickinson, Michael, Opat, Stephen, McQuilten, Zoe K, Wood, Erica M, St George, Gayathri, Hawkes, Eliza A

“…Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d'Etude des Lymphomes…”
Get full text

Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project by Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen, Hawkes, Eliza A.

“…Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma…”
Get full text

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake by SCOTT, Andrew M, LEE, Fook-Thean, RIGOPOULOS, Angela, STURROCK, Susan, MURPHY, Roger, WIRTH, Veronika, MURONE, Carmel, SMYTH, Fiona E, KNIGHT, Simon, WELT, Sydney, RITTER, Gerd, RICHARDS, Elizabeth, JONES, Robert, NICE, Edouard C, BURGESS, Antony W, OLD, Lloyd J, HOPKINS, Wendie, MACGREGOR, Duncan, CEBON, Jonathan S, HANNAH, Anthony, CHONG, Geoffrey, PAUL, U, PAPENFUSS, Anthony

“…Purpose: To determine the in vivo characteristics of huA33, a CDR-grafted humanized antibody against the A33 antigen, we have conducted an open-label, dose…”
Get full text

A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen by SCOTT, Andrew M, TEBBUTT, Niall, MACGREGOR, Duncan, PAPENFUSS, Anthony T, CHAPPELL, Bridget, SAUNDER, Timothy H, BRECHBIEL, Martin W, DAVIS, Ian D, MURPHY, Roger, CHONG, Geoffrey, HOFFMAN, Eric W, OLD, Lloyd J, LEE, Fook-Thean, CAVICCHIOLO, Tina, ZHANQI LIU, GILL, Sanjeev, POON, Aurora M. T, HOPKINS, Wendie, SMYTH, Fiona E, MURONE, Carmel

“…Purpose: We report a first-in-man trial of a humanized antibody (hu3S193) against the Le y antigen. Experimental Design: Patients with advanced Le y -positive…”
Get full text

The value of semiquantitative PET features and end-of-therapy PET in grade 3B follicular lymphoma by Barraclough, Allison, Lee, Sze Ting, Villa, Diego, Hapgood, Greg, Wilson, Don, Chong, Geoffrey, Hawkes, Eliza A

“…Grade 3B follicular lymphoma (G3BFL) is a rare lymphoma thought to sit on a continuum between low-grade FL and diffuse large B-cell lymphoma (DLBCL). The…”
Get full text

Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years by Loh, Zoe, Salvaris, Ross, Chong, Geoffrey, Churilov, Leonid, Manos, Kate, Barraclough, Allison, Hawkes, Eliza A.

“…Summary Eligibility criteria for randomised control trials (RCT) in diffuse large B‐cell lymphoma (DLBCL) may be becoming increasingly strict. In this…”
Get full text

Capability evaluation of a large regional clinical trials unit to assess growth over time by Bell, Lisa Ann, Pitman, Ethan, Goss, Carmel, Clarke, Ashleigh, Gurnett, Rebecca, Murphy, Virginia, Chong, Geoffrey, Faisal, Wasek

“…e13671 Background: Participation in clinical trials is associated with better health outcomes, however prevalence of clinical trial participation among…”
Get full text

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma by Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles

“…Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol…”
Get full text

Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory? by Hawkes, Eliza A, Chong, Geoffrey, Grigg, Andrew

Get full text

Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma by CHONG, Geoffrey, LEE, Fookthean, MURPHY, Roger, WIRTH, Veronika, SMYTH, Fiona E, POTASZ, Nicole, POON, Aurora, DAVIS, Ian D, SAUNDER, Tim, O'KEEFE, Graeme J, BURGESS, Antony W, HOFFMAN, Eric W, HOPKINS, Wendie, OLD, Lloyd J, SCOTT, Andrew M, TEBBUTT, Niall, CEBON, Jonathan S, MOUNTAIN, Angela J, CHAPPELL, Bridget, PAPENFUSS, Anthony, SCHLEYER, Paul, PAUL, U

“…Purpose: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown…”
Get full text

Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic by Loh, Zoe, Hawkes, Eliza A., Chionh, Fiona, Azad, Arun, Chong, Geoffrey

“…Prompt and accurate diagnosis of lymphadenopathy is important, yet there is wide variability in clinical approach and referral patterns, leading to unnecessary…”
Get full text

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study by Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew, Hawkes, Eliza A.

“…Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimmunotherapy in diffuse large…”
Get full text

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up by Villasboas, Jose. C., Kim, Tae Min, Taszner, Michal, Novelli, Silvana, Cho, Seok-Goo, Merli, Michele, Jimenez Ubieto, Ana, Tessoulin, Benoit, Poon, Michelle, Walewski, Jan, Yi, Shuhua, Song, Yuqin, Chong, Geoffrey, Luminari, Stefano, Bachy, Emmanuel, Guidez, Stephanie, Alonso, Aranzazu, Jagadeesh, Deepa, Zhang, Wei, Magnano, Laura, Iskierka-Jażdżewska, Elżbieta, Tani, Monica, Cai, Jessica, Uppala, Amulya, Shariff, Saleem, Chi, Lei, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Tucker, David

“…Background The class of CD20×CD3 bispecific antibodies (BsAbs) has emerged as an important anti-lymphoma modality for patients (pts) with R/R B-cell…”
Get full text

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma by Tessoulin, Benoit, Cho, Seok-Goo, Taszner, Michal, Kim, Tae Min, Novelli, Silvana, Villasboas, Jose C., Merli, Michele, Jimenez Ubieto, Ana, Poon, Michelle, Tucker, David, Walewski, Jan, Yi, Shuhua, Song, Yuqin, Chong, Geoffrey, Bachy, Emmanuel, Guidez, Stephanie, Alonso, Aranzazu, Jagadeesh, Deepa, Zhang, Wei, Magnano, Laura, Iskierka-Jazdzewska, Elzbieta, Tani, Monica, Cai, Jessica, Ivanescu, Cristina, Reaney, Matthew, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Harnett, James, Chi, Lei, Luminari, Stefano

“…Background: Goals of patient-centered care for management of relapsed or refractory follicular lymphoma (R/R FL) are to improve clinical outcomes while…”
Get full text

A Randomized Controlled Trial of a Nurse‐Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer by Jefford, Michael, Gough, Karla, Drosdowsky, Allison, Russell, Lahiru, Aranda, Sanchia, Butow, Phyllis, Phipps‐Nelson, Jo, Young, Jane, Krishnasamy, Mei, Ugalde, Anna, King, Dorothy, Strickland, Andrew, Franco, Michael, Blum, Robert, Johnson, Catherine, Ganju, Vinod, Shapiro, Jeremy, Chong, Geoffrey, Charlton, Julie, Haydon, Andrew, Schofield, Penelope

“…Introduction. Colorectal cancer (CRC) and its treatments can cause distressing sequelae. We conducted a multicenter randomized controlled trial aiming to…”
Get full text

Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma by Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles

Get full text

Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies by Campbell, Robert, Chong, Geoffrey, Hawkes, Eliza A

“…Bruton's tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the…”
Get full text